objective: To evaluate thyroid function tests in chronic liver disease(CLD) patients and to find out whether the thyroid functions tests abnormalities if any correlate with the clinical severity or stage of CLD patients. Method: Cross sectional study, spanning over a period of one and half years involving one hundred CLD patients, carried out in a tertiary hospital in Kolkata. Results: The mean values of serum FT3 and FT4 showed a tendency to fall with progressive chronic liver disease and was statistically significant, more marked with FT3 (Child A vs B, p–<0.001; A vs C, p–<0.001; CLD stage 1 vs stage 2,p <0.001) than with FT4( Child A vs B, p 0.556; A vs C, p < 0.001, stage 1 vs stage 2, p 0.020). Changes of serum TSH with chronic liver disease was found not statistically significant . The fall of mean serum FT3 and FT4 values were also significant when compared independently in respect of ascites and no ascites (p–<0.001 & p–<0.007 respectively) and hepatic encephalopathy(HE) and no HE ( p <0.001; p 0.001 respectively). Significant changes of serum FT3 and FT4 values were noted with regard to rise of serum bilirubin(p–<0.001 & p–<0.001 respectively) and prothrombin prolongation time (p–<0.001 & p–0.001 resp.) but with regard to serum albumin significant changes was observed only Conclusion: Serum FT3 can be considered as a sensitive marker of hepatic function in chronic liver disease. However thyroid function tests with etiology based chronic liver disease would perhaps help better to understand thyroid dysfunction in chronic liver disease.